• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Coty Strengthens Consumer Beauty Business With Senior Talent

    12/2/20 3:00:00 AM ET
    $JNJ
    $COTY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $JNJ alert in real time by email

    NEW YORK--(BUSINESS WIRE)--Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies and the global leader in fragrances, today announced two leaders to drive its Consumer Beauty organization. Stefano Curti will join the company as Chief Brands Officer, Consumer Beauty, while Alexis Vaganay will be promoted to Chief Commercial Officer, Consumer Beauty. The appointments come as CEO Sue Y. Nabi strengthens her leadership team, following the recent additions of Isabelle Bonfanti as Chief Commercial Officer, Luxury, and Jean-Denis Mariani as Chief Digital Officer.

    Stefano Curti joins Coty this week as Chief Brands Officer, Consumer Beauty and will be based in New York. Curti – who has a strong track record of brand building and channel expansions – will focus on strengthening the division’s brand equity, global positioning and innovation performance. He brings a wealth of senior international experience, having spent almost 30 years working in the beauty and health industry in the U.S., Europe and Latin America. Curti joins from Markwins Beauty Brands – the largest independent cosmetics company in the U.S., with established mass cosmetics brands including Physicians Formula, LORAC, Black Radiance and WetnWild – where he served as Global President. He spent 22 years at Johnson & Johnson, where he progressed through the marketing organization to the role of Global President Beauty and Baby divisions. During his time at J&J, Curti led iconic skin and personal care brands like Aveeno, Clean & Clear and Neutrogena, driving above-market sales growth and double-digit profit growth for the beauty portfolio.

    Coty also announced the promotion of Alexis Vaganay to Chief Commercial Officer, Consumer Beauty. Vaganay, who has more than 20 years’ experience in international sales and marketing, takes up his appointment this week and will be based in Coty’s Amsterdam headquarters. He will be responsible for leading Coty’s regions - in close collaboration with his Luxury counterpart - and developing Consumer Beauty’s commercial strategy to increase market share and grow revenues in color cosmetics, body care and consumer fragrances. Most recently, Vaganay was EVP, EMEA, following four years as General Manager of UK&I Luxury. Under his leadership, Coty UK&I was among the fastest growing luxury fragrance players. Prior to joining Coty in 2016, Vaganay worked at Unilever and Bic in a variety of global roles.

    Sue Y. Nabi, CEO of Coty, said, “My ambition from day one has been to quickly build a first-class leadership team. The appointment of these two leaders means we are now in great shape to re-position our portfolio of brands more clearly. Stefano’s track record and sector expertise makes him the right leader for our Consumer Beauty transformation. Alexis, likewise, is a proven leader within Coty and his deep knowledge of our business and brands makes him the perfect fit to accelerate our growth on all continents.”

    Nabi continued: “Consumer Beauty is a critical pillar of our business. In times of uncertainty, the consumer beauty industry has an essential mission: the place where people can access the latest trends and innovations, find the best quality at an accessible price and experience the diversity of all kinds of beauties. That’s why we are excited that Coty has found two beauty champions who will enable our portfolio of meaningful brands - which include COVERGIRL, Sally Hansen, Rimmel, Bourjois, adidas and David Beckham, to name a few - to truly thrive.”

    In October, Coty announced the appointment of Isabelle Bonfanti as Chief Commercial Officer, Luxury. She boasts more than 30 years’ experience in international brand development and transformation, including 17 years in L’Oréal’s Luxury division. Bonfanti was joined by Jean-Denis Mariani as Chief Digital Officer, who joined from Guerlain as Coty continues to generate record e-commerce sales across its portfolio.

    About Coty Inc.

    Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, and skin and body care. Coty is the global leader in fragrance and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com.

    Get the next $JNJ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNJ
    $COTY

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Coty Inc.
    $COTY
    5/8/2025$5.00Buy → Hold
    Canaccord Genuity
    Coty Inc.
    $COTY
    4/17/2025Outperform → Mkt Perform
    Raymond James
    Coty Inc.
    $COTY
    4/15/2025$4.50Buy → Underperform
    BofA Securities
    Coty Inc.
    $COTY
    4/11/2025$5.65Outperform → Neutral
    Exane BNP Paribas
    Coty Inc.
    $COTY
    3/27/2025$6.00 → $5.00Underweight
    Barclays
    Coty Inc.
    $COTY
    3/25/2025$7.50Buy
    Berenberg
    Coty Inc.
    $COTY
    3/20/2025$7.00 → $8.00Neutral → Buy
    Citigroup
    More analyst ratings

    $JNJ
    $COTY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

      Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

      5/28/25 4:43:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jessica Dean Named to National Law Journal's 2025 Elite Women of the Plaintiffs Bar

      Dean Omar Branham Shirley partner honored for holding corporate giants accountable Premier plaintiffs firm Dean Omar Branham Shirley, LLP, is proud to announce that partner Jessica Dean has been named to The National Law Journal's 2025 Elite Women of the Plaintiffs Bar, honoring women lawyers who have achieved exceptional results in high-stakes litigation on behalf of plaintiffs. "I'm truly honored by this recognition," said Ms. Dean. "I care deeply about my clients and so appreciate the nod towards my life's work." Ms. Dean has built a national reputation for holding powerful corporations accountable, with a primary focus in recent years on litigation against Johnson & Johnson (NYSE:

      5/27/25 10:07:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Panel Reiterates the Cancer Risks of Talc

      Links of ovarian cancer to baby powder use raise concerns about use in cosmetics, food, drugs A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer products such as gum, candy, rice and pharmaceuticals. Many of the experts cited the more than 30 years of studies showing an association between talc use and ovarian cancer, which led Johnson & Johnson (NYSE:JNJ) to remove the company's iconic body powders from the market in recent years. "It's clear (talc) is carcinogenic and inflammatory and there's very little doubt about this," said Dr. George Tidmarsh, an acclaimed pediatric ne

      5/23/25 8:00:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $COTY
    SEC Filings

    See more
    • SEC Form SD filed by Coty Inc.

      SD - COTY INC. (0001024305) (Filer)

      5/30/25 4:31:41 PM ET
      $COTY
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form SD filed by Johnson & Johnson

      SD - JOHNSON & JOHNSON (0000200406) (Filer)

      5/28/25 4:05:16 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 13F-HR filed by Johnson & Johnson

      13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

      5/7/25 4:47:35 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $COTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Johnson & Johnson

      SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

      4/10/24 5:12:55 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      2/13/24 5:07:58 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      1/30/24 12:46:49 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $COTY
    Financials

    Live finance-specific insights

    See more
    • Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

      Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

      5/28/25 4:43:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coty Reports Q3 Results And Shares Multi-Pronged Plan of Attack to Fuel Momentum in FY26 and Beyond

      Q3 Results and Near-Term Outlook Reflect Complex Operating Environment Strong Focus on Protecting Profitability and Cash Flow All-In to Win Transformation Program to Boost Agility, Scale and Efficiency Robust Pipeline of Launches, Distribution Expansion and Adjacent Opportunities for FY26 Updates Fiscal 2025 Outlook Regulatory News: Coty Inc. (NYSE:COTY) (PARIS:COTY) ("Coty" or "the Company") today announced its results for the first nine months and third quarter of fiscal year 2025, ended March 31, 2025. While an uncertain market backdrop and FX headwinds led to declining Q3 sales, Coty has built robust plans to fuel operational and financial improvement in FY26 and beyond. "Across

      5/6/25 4:30:00 PM ET
      $COTY
      Package Goods/Cosmetics
      Consumer Discretionary
    • Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the close of business on May 27, 2025. The ex-dividend date is May 27, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, trea

      4/15/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $COTY
    Leadership Updates

    Live Leadership Updates

    See more
    • Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

      WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

      3/25/25 1:11:06 PM ET
      $JNJ
      $TVGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Coty Hosts Expert Panel to Bust Beauty Myths and #UndefineBeauty

      Experts discuss the impacts of restrictive beauty standards Urges major English dictionary publishers to revise outdated definitions of beauty Invites the public to sign the #UndefineBeauty petition at change.org Coty (NYSE:COTY) (PARIS:COTY), one of the world's largest beauty companies, with an iconic portfolio of brands across fragrance, color cosmetics, skin and body care, hosted a cross-industry roundtable to discuss restrictive beauty ideals and definitions. As the next chapter of the award-winning #UndefineBeauty campaign, the panel debunks beauty myths and includes perspectives on neuroscience, art, social media, sociology, and mental health, and underscores the need for colle

      3/18/25 7:00:00 AM ET
      $COTY
      Package Goods/Cosmetics
      Consumer Discretionary
    • Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

      Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are effective May 1, 2025, and Mr. Snellgrove as well as Ms. Moore, will continue to report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph Wolk. "Today's announcement reflects the deep bench of talent within Johnson & Johnson as well

      3/4/25 4:15:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $COTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 92% to 29,795 units (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      5/5/25 5:10:14 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Woods Eugene A.

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      4/28/25 5:57:54 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director West Nadja

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      4/28/25 5:54:13 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $COTY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $COTY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Parize Isabelle bought $50,138 worth of shares (4,775 units at $10.50), increasing direct ownership by 8% to 61,500 units (SEC Form 4)

      4 - COTY INC. (0001024305) (Issuer)

      10/10/23 4:23:44 PM ET
      $COTY
      Package Goods/Cosmetics
      Consumer Discretionary
    • Parize Isabelle bought $210,945 worth of shares (20,500 units at $10.29), increasing direct ownership by 57% to 56,725 units (SEC Form 4)

      4 - COTY INC. (0001024305) (Issuer)

      10/6/23 9:06:02 PM ET
      $COTY
      Package Goods/Cosmetics
      Consumer Discretionary

    $JNJ
    $COTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coty downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Coty from Buy to Hold and set a new price target of $5.00

      5/8/25 8:26:20 AM ET
      $COTY
      Package Goods/Cosmetics
      Consumer Discretionary
    • Coty downgraded by Raymond James

      Raymond James downgraded Coty from Outperform to Mkt Perform

      4/17/25 8:29:04 AM ET
      $COTY
      Package Goods/Cosmetics
      Consumer Discretionary